Victory Capital Management
AKBA icon

Victory Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Victory Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180K Sell
129,170
-121,367
-48% -$167K ﹤0.01% 2209
2025
Q4 		$403K Sell
250,537
-35,848
-13% -$75.1K ﹤0.01% 2071
2025
Q3 		$782K Buy
286,385
+256,353
+854% +$853K ﹤0.01% 1953
2025
Q2 		$109K Buy
30,032
+4,768
+19% +$13.1K ﹤0.01% 2318
2025
Q1 		$48.5K Sell
25,264
-417
-2% -$851 ﹤0.01% 2367
2024
Q4 		$48.8K Buy
25,681
+336
+1% +$583 ﹤0.01% 2399
2024
Q3 		$33.5K Buy
25,345
+518
+2% +$692 ﹤0.01% 2419
2024
Q2 		$25.3K Buy
24,827
+3,010
+14% +$3.72K ﹤0.01% 2412
2024
Q1 		$39.9K Sell
21,817
-702
-3% -$1.12K ﹤0.01% 2393
2023
Q4 		$27.9K Sell
22,519
-732,969
-97% -$748K ﹤0.01% 2485
2023
Q3 		$861K Buy
755,488
+93,590
+14% +$120K ﹤0.01% 1732
2023
Q2 		$606K Buy
661,898
+404,154
+157% +$390K ﹤0.01% 1902
2023
Q1 		$144K Buy
257,744
+237,922
+1,200% +$182K ﹤0.01% 2305
2022
Q4 		$11.4K Sell
19,822
-8
-0% -$3 ﹤0.01% 2539
2022
Q3 		$6K Sell
19,830
-4,148
-17% -$1.63K ﹤0.01% 2675
2022
Q2 		$8K Buy
23,978
+965
+4% +$405 ﹤0.01% 2663
2022
Q1 		$10K Sell
23,013
-657
-3% -$1.41K ﹤0.01% 2679
2021
Q4 		$53K Sell
23,670
-677
-3% -$1.85K ﹤0.01% 2636
2021
Q3 		$70K Buy
24,347
+883
+4% +$2.52K ﹤0.01% 2658
2021
Q2 		$89K Buy
23,464
+276
+1% +$929 ﹤0.01% 2611
2021
Q1 		$78K Buy
23,188
+669
+3% +$2.41K ﹤0.01% 2627
2020
Q4 		$63K Buy
22,519
+1,330
+6% +$3.88K ﹤0.01% 2446
2020
Q3 		$53K Sell
21,189
-1,138
-5% -$9.99K ﹤0.01% 2385
2020
Q2 		$303K Sell
22,327
-15,585
-41% -$161K ﹤0.01% 2171
2020
Q1 		$288K Buy
37,912
+7,801
+26% +$60.7K ﹤0.01% 2243
2019
Q4 		$190K Buy
30,111
+10,163
+51% +$48.3K ﹤0.01% 2322
2019
Q3 		$78K Buy
+19,948
New +$85.5K ﹤0.01% 2518

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Victory Capital Management's AKBA Position: Q1 2026 in Review

Victory Capital Management reduced its Akebia Therapeutics (AKBA) stake by 48% in Q1 2026, selling an estimated $167K and leaving 129,170 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #2209.

Victory Capital Management first reported a position in AKBA in Q3 2019 and has held it in 27 quarters since. The position peaked at $861K in Q3 2023. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Victory Capital Management held 129,170 shares of Akebia Therapeutics worth $180K as of Q1 2026.
  • Victory Capital Management sold 121,367 Akebia Therapeutics shares in Q1 2026, an estimated $167K.
  • Akebia Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2209 holding.
  • Victory Capital Management first reported a position in Akebia Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Victory Capital Management's Akebia Therapeutics position peaked at $861K in Q3 2023.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.